Please login to the form below

Not currently logged in

Large antibody order for AbD Serotec

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

Proteomika SL has placed a large order for multi research antibodies with MorphoSys AG's AbD Serotec business unit.

The Spanish biotech company, which specialises in biomarker technology, will be taking advantage of MorphoSys AG's HuCAL Gold (a powerful antibody library) based novel research antibodies.

This order will rank Proteomika, which is actively involved in cancer research/discovery programmes, as one of MorphoSys AG's largest customers

Dr Simon Moroney, CEO of MorphoSys AG, said: "This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications.

"We welcome the decision of Proteomika to use HuCAL Gold research antibodies in its proteomics programs."

A subsidiary of Progenika Biopharma SA, Proteomika was set up to exploit advances in biomarker research for the development of diagnostic and prognostic products.

Since its creation in 2002, the firm has established research collaborations with pharma and biotech companies aiming to validate non-invasive diagnostic and pharmacoproteomics.

Dr Laureano Simon, CEO of Proteomika, said: "The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation."

Neither company involved in the deal has released financial details of the agreement.

5th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....